Lv1
22 积分 2024-10-20 加入
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
6天前
已完结
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
6天前
已完结
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
6天前
已完结
Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study
6天前
已完结
Hepatocellular Carcinoma: Pick the Winner—Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent–Based Combinations
6天前
已完结
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
6天前
已完结
Active repression of cell fate plasticity by PROX1 safeguards hepatocyte identity and prevents liver tumorigenesis
1个月前
已完结
Research progress in the correlation between ctDNA and hepatocellular carcinoma
2个月前
已完结
Carbon Dioxide, Blood Pressure, and Perioperative Stroke: A Retrospective Case–Control Study
2个月前
已完结
Abernethy Malformations: Evaluation and Management of Congenital Portosystemic Shunts
3个月前
已完结
皖公网安备34019202002308
